GLENMARK · Healthcare
Glenmark Pharmaceuticals Ltd. reported revenue of ₹2,507 cr for October to December 2023, — on the year and −21.8% on the quarter.
Operating profit (EBITDA) was −₹209 cr, a margin of −8.3%, — on the year and −2,274 bps on the quarter.
The net loss was ₹331 cr, with earnings per share of −₹12.45.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Could not run on this quarter: Headline vs core profit, Other income carrying profit, Exceptional items that recur, Operating margin on the year, Depreciation falling, Finance cost rising, Swing to loss or profit, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3,207 cr | ₹2,507 cr | ₹3,063 cr | ₹3,244 cr | ₹3,434 cr | ₹3,388 cr | ₹3,256 cr | ₹3,264 cr | ₹6,047 cr | ₹3,901 cr | ₹3,771 cr | ₹4,018 cr |
| YoY | — | — | — | +7% | +7% | +35% | +6% | +1% | +76% | +15% | +16% | +23% |
| EBITDA margin | 14.4% | −8.3% | 16.5% | 18.1% | 17.5% | 17.7% | 17.2% | 17.8% | 39.0% | 22.3% | 20.2% | 20.0% |
| Other income, % of PBT | — | — | 63% | 7% | 8% | 7% | −4,513% | −309% | −122% | −26% | −47% | 10% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | — | — | — | 26% | 25% | 24% | 45% | 51% | 37% | 24% | 22% | 25% |
| Net profit | −₹62.0 cr | −₹331 cr | −₹1,214 cr | ₹340 cr | ₹354 cr | ₹348 cr | ₹4.0 cr | ₹47.0 cr | ₹610 cr | ₹403 cr | ₹301 cr | ₹483 cr |
| YoY | — | — | — | +97% | — | — | — | −86% | +72% | +16% | +7,425% | +928% |
| Core profit YoY | — | — | — | +136% | +118% | — | +81% | −9% | +396% | +59% | +55% | +47% |
| EPS | −₹2.90 | −₹12.45 | −₹43.17 | ₹12.06 | ₹12.55 | ₹12.33 | ₹0.16 | ₹1.66 | ₹21.63 | ₹14.29 | ₹10.68 | ₹17.11 |
| Flags | · | · | 1 | 1 | 1 | 1 | 1 | ✓ | ✓ | 1 | 2 | 1 |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Glenmark Pharmaceuticals Ltd. reported revenue of ₹2,507 cr (— on the year) and net profit of −₹331 cr (— on the year) for October to December 2023.
None of the 1 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.